Código QR

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma

BackgroundDespite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody rituximab and the CD19-targeting antibody tafasitamab share distinct modes of actions,...

Descrición completa

Gardado en:
Principais autores: Maria Patra-Kneuer, Gaomei Chang, Wendan Xu, Christian Augsberger, Michael Grau, Myroslav Zapukhlyak, Kristina Ilieva, Karin Landgraf, Doris Mangelberger-Eberl, Kasra Yousefi, Philipp Berning, Katrin S. Kurz, German Ott, Pavel Klener, Cyrus Khandanpour, Pedro Horna, Jürgen Schanzer, Stefan Steidl, Jan Endell, Christina Heitmüller, Georg Lenz
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Assuntos:
antibody therapy
lymphoma
tumor immunology
CD19
CD20
tafasitamab
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1220558/full
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares